934537-35-6

Basic information

• Product Name: N-(2-chloro-6-methoxyphenyl)-2,2-dimethylpropionamide
• Synonyms: N-(2-chloro-6-methoxyphenyl)-2,2-dimethylpropionamide
• CAS NO: 934537-35-6
• Molecular Weight: 241.718
• Mol File: 934537-35-6.mol

Chemical Properties

• CAS DataBase Reference: N-(2-chloro-6-methoxyphenyl)-2,2-dimethylpropionamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-chloro-6-methoxyphenyl)-2,2-dimethylpropionamide(934537-35-6)
• EPA Substance Registry System: N-(2-chloro-6-methoxyphenyl)-2,2-dimethylpropionamide(934537-35-6)

Safety Data

• Hazardous Substances Data: 934537-35-6(Hazardous Substances Data)

Upstream product

• 90-04-0 2-methoxy-phenylamine 
• 3282-30-2 pivaloyl chloride 
• 33768-49-9 N-(2-methoxyphenyl)pivalamide 

Downstream Products

• 1345459-58-6 2-bromo-2,2-difluoro-N-(2-hydroxy-6-chlorophenyl)acetamide 
• 56962-00-6 2-amino-3-chlorophenol 
• 158966-62-2 6-chloro-o-anisidine 

Relevant articles and documents

Difluoromethylbenzoxazole pyrimidine thioether derivatives: A novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors

This paper reports the synthesis and antiviral properties of new difluoromethylbenzoxazole (DFMB) pyrimidine thioether derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. By use of a combination of structural biology study and traditional medicinal chemistry, several members of this novel class were synthesized using a single electron transfer chain process (radical nucleophilic substitution, SRN1) and were found to be potent against wild-type HIV-1 reverse transcriptase, with low cytotoxicity but with moderate activity against drug-resistant strains. The most promising compound 24 showed a significant EC50 value close to 6.4 nM against HIV-1 IIIB, a moderate EC50 value close to 54 μM against an NNRTI resistant double mutant (K103N + Y181C), but an excellent selectivity index >15477 (CC50 > 100 μM).

BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided the use of a compound of formula (I),wherein Y, W1 to W4, Z1 to Z4 and R have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicame